Central Nervous System

Beckley Psytech reports initial positive data from TRD treatment trial

Beckley Psytech has released initial positive findings from its Phase IIa clinical study of BPL-003 for treating treatment-resistant depression (TRD).…

AriBio licenses Alzheimer’s pill in China for up to $770m

AriBio has signed off on exclusive marketing rights for its Alzheimer’s disease treatment candidate AR1001 in China. The deal, with…

Roche subsidiary upset with Phase III gMG trial despite meeting endpoint

A Phase III study of Chugai Pharmaceuticals’ Enspryng (satralizumab) in generalised myasthenia gravis (gMG) has not met the company’s expectations,…

Usona Institute begins Phase III trial of psilocybin for MDD

Medical research organisation Usona Institute has commenced a Phase III clinical trial to evaluate the potential of psilocybin as a…

Donanemab: FDA AdCom will put spotlight on tau enrolment and ARIA concerns

In May 2023, pharma giant Eli Lilly looked as if it was onto a winner after publishing positive topline data…

Developer behind wearable device for Tourettes syndrome secures $3.2m

Neupulse, a UK-based company that is developing a wristband to help manage the symptoms of Tourette's syndrome, has raised $3.2m…

Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints

This week on Pipeline Moves, we kick off by looking at success of a Phase III trial of Ironwood Pharmaceuticals’…

SciSparc doses first patient with CBD-containing drug in autism trial

Israel-based pharma company SciSparc has kicked off a trial evaluating its SCI-210 compound in children and adolescents with autism spectrum…

SetPoint wins second FDA breakthrough device nod for neurostim device

SetPoint Medical has a breakthrough device designation for its neuroimmune modulation device for the treatment of relapsing-remitting multiple sclerosis (RRMS).…

Acadia’s schizophrenia drug trial fails to meet primary endpoint

US-based biopharmaceutical company Acadia Pharmaceuticals has reported that its Phase III ADVANCE-2 clinical trial of pimavanserin for the treatment of…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close